blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3218392

EP3218392 - MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  04.06.2021
Database last updated on 24.04.2024
FormerThe patent has been granted
Status updated on  26.06.2020
FormerGrant of patent is intended
Status updated on  11.03.2020
FormerExamination is in progress
Status updated on  11.06.2019
FormerRequest for examination was made
Status updated on  18.08.2017
FormerThe international publication has been made
Status updated on  14.04.2017
Most recent event   Tooltip04.06.2021No opposition filed within time limitpublished on 07.07.2021  [2021/27]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[2017/38]
Inventor(s)01 / GILLMAN, Kevin W.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492 / US
02 / GOODRICH, Jason
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492 / US
03 / BOY, Kenneth M.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492 / US
04 / ZHANG, Yunhui
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492 / US
05 / MAPELLI, Claudio
465 Briggs Road
Langhorne, PA 19047 / US
06 / POSS, Michael A.
c/o Bristol-Myers Squibb Company
Route 206 & Province Line Road
Princeton, New Jersey 08543 / US
07 / SUN, Li-Qiang
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492 / US
08 / ZHAO, Qian
93 Hintz Drive
Wallingford, CT 06492 / US
09 / MULL, Eric
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492 / US
10 / GILLIS, Eric P.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492 / US
11 / SCOLA, Paul Michael
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492 / US
12 / LANGLEY, David, R.
c/o Bristol-Myers Squibb Company
5 Research Parkway
Wallingford, Connecticut 06492 / US
13 / MEANWELL, M. Nicholas
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
 [2017/38]
Representative(s)Kling, Edouard
Swords Laboratories, Ireland
Swiss Branch, Steinhausen
Hinterbergstrasse 16
6312 Steinhausen / CH
[2020/31]
Former [2017/38]Kling, Edouard
Swords Laboratories, Ireland
Swiss Branch, Steinhausen
Hinterbergstrasse 16
6330 Cham / CH
Application number, filing date15801052.012.11.2015
[2017/38]
WO2015US60265
Priority number, dateUS201462079944P14.11.2014         Original published format: US 201462079944 P
US201562111388P03.02.2015         Original published format: US 201562111388 P
US201562204689P13.08.2015         Original published format: US 201562204689 P
[2017/38]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016077518
Date:19.05.2016
Language:EN
[2016/20]
Type: A1 Application with search report 
No.:EP3218392
Date:20.09.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 19.05.2016 takes the place of the publication of the European patent application.
[2017/38]
Type: B1 Patent specification 
No.:EP3218392
Date:29.07.2020
Language:EN
[2020/31]
Search report(s)International search report - published on:EP19.05.2016
ClassificationIPC:C07K7/08, C07K7/56, G01N33/68, A61K38/12, A61P37/06
[2017/38]
CPC:
C07K7/08 (EP,CN,IL,US); C07D201/00 (IL); C07K7/56 (EP,CN,IL,KR,US);
A61K38/00 (EP,CN,IL,KR,US); A61K38/10 (EP,IL,US); A61K45/06 (EP,IL,KR,US);
A61K51/088 (EP,IL,US); A61P1/04 (EP); A61P1/16 (EP);
A61P1/18 (EP); A61P11/00 (EP); A61P13/08 (EP);
A61P13/12 (EP); A61P15/00 (EP); A61P17/00 (EP);
A61P31/00 (EP); A61P31/04 (EP); A61P31/12 (EP);
A61P31/14 (EP); A61P31/16 (EP); A61P31/18 (EP);
A61P31/20 (EP); A61P31/22 (EP); A61P35/00 (EP);
A61P35/04 (EP); A61P37/02 (EP); A61P37/04 (EP);
A61P37/06 (EP); A61P43/00 (EP); A61P7/00 (EP);
Y02A50/30 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/38]
Extension statesBA13.04.2017
ME13.04.2017
Validation statesMA13.04.2017
MD13.04.2017
TitleGerman:ALS IMMUNMODULATOREN GEEIGNETE MAKROCYCLISCHE PEPTIDE[2020/09]
English:MACROCYCLIC PEPTIDES USEFUL AS IMMUNOMODULATORS[2017/38]
French:PEPTIDES MACROCYCLIQUES UTILES COMME IMMUNOMODULATEURS[2020/09]
Former [2017/38]ALS IMMUNMODULATOREN NÜTZLICHE, MAKROCYCLISCHE PEPTIDE
Former [2017/38]PEPTIDES MACROCYCLIQUES UTILES COMME IMMUNOMOLDULATEURS
Entry into regional phase13.04.2017National basic fee paid 
13.04.2017Designation fee(s) paid 
13.04.2017Examination fee paid 
Examination procedure13.04.2017Examination requested  [2017/38]
13.04.2017Date on which the examining division has become responsible
14.12.2017Amendment by applicant (claims and/or description)
14.06.2019Despatch of a communication from the examining division (Time limit: M04)
29.08.2019Reply to a communication from the examining division
12.03.2020Communication of intention to grant the patent
18.06.2020Fee for grant paid
18.06.2020Fee for publishing/printing paid
18.06.2020Receipt of the translation of the claim(s)
Divisional application(s)EP20182343.2  / EP3778622
Opposition(s)30.04.2021No opposition filed within time limit [2021/27]
Fees paidRenewal fee
13.11.2017Renewal fee patent year 03
14.11.2018Renewal fee patent year 04
14.11.2019Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]WO2014151634  (BRISTOL MYERS SQUIBB CO [US]) [X] 1-37 * page 1, line 4 - page 14, line 7 * * page 62, line 27 - page 85, line 11 ** claim - *
by applicantUS4439196
 US4447233
 US4447224
 US4475196
 US4486194
 US4487603
 US4522811
 US4596556
 US4790824
 US4941880
 US5064413
 US5312335
 US5374548
 US5383851
 US5399163
 US5399331
 US5416016
 US5811097
 US5837243
 US5922845
 WO2007005874
 US7488802
 US8008449
 US8168757
    - OKAZAKI ET AL., CURR. OPIN. IMMUNOL., (2002), vol. 14, pages 779 - 782
    - BENNETT ET AL., J. IMMUNOL., (2003), vol. 170, pages 711 - 718
    - AGATA ET AL., INT. IMMUNOL., (1996), vol. 8, pages 765 - 772
    - THOMAS, M.L., J. EXP. MED., (1995), vol. 181, pages 1953 - 1956
    - VIVIER, E. ET AL., IMMUNOL. TODAY, (1997), vol. 18, pages 286 - 291
    - FREEMAN ET AL., J. EXP. MED., (2000), vol. 192, pages 1027 - 1034
    - LATCHMAN ET AL., NAT. IMMUNOL., (2001), vol. 2, pages 261 - 268
    - CARTER ET AL., EUR. J. IMMUNOL., (2002), vol. 32, pages 634 - 643
    - DONG ET AL., NAT. MED., (2002), vol. 8, pages 787 - 789
    - DONG ET AL., J. MOL. MED., (2003), vol. 81, pages 281 - 287
    - BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER., (2005), vol. 54, pages 307 - 314
    - KONISHI ET AL., CLIN. CANCER RES., (2004), vol. 10, pages 5094 - 5100
    - IWAI ET AL., PROC. NATL. ACAD. SCI. USA, (2002), vol. 99, pages 12293 - 12297
    - BROWN ET AL., J. IMMUNOL., (2003), vol. 170, pages 1257 - 1266
    - BUTTE MJ ET AL., IMMUNITY, (2007), vol. 27, pages 111 - 122
    - PATERSON AM ET AL., J IMMUNOL., (2011), vol. 187, pages 1097 - 1105
    - YANG J ET AL., JLMMUNOL., (20110801), vol. 187, no. 3, pages 1113 - 9
    - KEIR, M.E. ET AL., ANNU. REV. IMMUNOL., (2008), vol. 26
    - DONG, H. ET AL., "B7-Hl pathway and its role in the evasion of tumor immunity", J. MOL. MED., (2003), vol. 81, no. 5, pages 281 - 287
    - DONG, H. ET AL., "Tumor-associated B7-Hl promotes T-cell apoptosis: a potential mechanism of immune evasion", NAT. MED., (2002), vol. 8, no. 8, pages 793 - 800
    - BARBER, D.L. ET AL., "Restoring function in exhausted CD8 T cells during chronic viral infection", NATURE, (2006), vol. 439, no. 7077, pages 682 - 687
    - YANG J. ET AL., J IMMUUOL., (20110801), vol. 187, no. 3, pages 1113 - 9
    - HA, S.J. ET AL., "Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection", J. EXP. MED., (2008), vol. 205, no. 3, pages 543 - 555
    - FINNEFROCK, A.C. ET AL., "PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination", J. IMMUNOL., (2009), vol. 182, no. 2, pages 980 - 987
    - SONG, M.-Y. ET AL., "Enhancement of vaccine-induced primary and memory CD8+ t-cell responses by soluble PD-1", J. IMMUNOTHER., (2011), vol. 34, no. 3, pages 297 - 306
    - MURATA, AM. J. PATHOL., (1999), vol. 155, pages 453 - 460
    - BALZANO, INT. J. CANCER SUPPL., (1992), vol. 7, pages 28 - 32
    - BERGE, S.M. ET AL., J. PHARM. SCI., (1977), vol. 66, pages 1 - 19
    - RANADE, V.V., J. CLIN. PHARMACOL., (1989), vol. 29, page 685
    - UMEZAWA ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., (1988), vol. 153, page 1038
    - BLOEMAN, P.G. ET AL., FEBS LETT., (1995), vol. 357, page 140
    - OWAIS, M. ET AL., ANTIMICROB. AGENTS CHEMOTHER., (1995), vol. 39, page 180
    - BRISCOE ET AL., AM. J. PHYSIOL., (1995), vol. 1233, page 134
    - SCHREIER ET AL., J. BIOL. CHEM., (1994), vol. 269, page 9090
    - KEINANEN, K. ET AL., FEBS LETT., (1994), vol. 346, page 123
    - KILLION, J.J. ET AL., IMMUNOMETHODS, (1994), vol. 4, page 273
    - IWAI ET AL., PROC. NATL. ACAD. SCI., (2002), vol. 99, pages 12293 - 12297
    - IWAI ET AL., INT. IMMUNOL., (2005), vol. 17, pages 133 - 144
    - HE ET AL., J. IMMUNOL., (2004), vol. 173, pages 4919 - 4928
    - ROSENBERG, S., Development of Cancer Vaccines, ASCO EDUCATIONAL BOOK SPRING, (2000), pages 60 - 62
    - LOGOTHETIS, C., DEVELOPPEMENT OF CANCER VACCINES, ASCO EDUCATIONAL BOOK SPRING, (2000), pages 300 - 302
    - KHAYAT, D., DEVELOPPEMENT OF CANCER VACCINES, ASCO EDUCATIONAL BOOK SPRING, (2000), pages 414 - 428
    - FOON, K., DEVELOPPEMENT OF CANCER VACCINES, ASCO EDUCATIONAL BOOK SPRING, (2000), pages 730 - 738
    - "Cancer Vaccines", RESTIFO, N. ET AL., Cancer: Principles and Practice of Oncology, (1997), pages 3023 - 3043
    - DRANOFF ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 3539 - 3543
    - ROSENBERG, S.A., IMMUNITY, (1999), vol. 10, pages 281 - 287
    - KIM, N ET AL., SCIENCE, (1994), vol. 266, pages 2011 - 2013
    - SUOT, R. ET AL., SCIENCE, (1995), vol. 269, pages 1585 - 1588
    - TAMURA, Y. ET AL., SCIENCE, (1997), vol. 278, pages 117 - 120
    - NESTLE, F. ET AL., NAT. MED., (1998), vol. 4, pages 328 - 332
    - KUGLER, A. ET AL., NAT. MED., (2000), vol. 6, pages 332 - 336
    - MOKYR, M. ET AL., CANCER RES., (1998), vol. 58, pages 5301 - 5304
    - KEHRL, J. ET AL., J. EXP. MED., (1986), vol. 163, pages 1037 - 1050
    - HOWARD, M. ET AL., IMMUNOLOGY TODAY, (1992), vol. 13, pages 198 - 200
    - HAHNE, M. ET AL., SCIENCE, (1996), vol. 274, pages 1363 - 1365
    - RIDGE, J. ET AL., NATURE, (1998), vol. 393, pages 474 - 478
    - ITO, N. ET AL., IMMUNOBIOLOGY, (2000), vol. 201, no. 5, pages 527 - 540
    - WEINBERG, A. ET AL., IMMUNOL., (2000), vol. 164, pages 2160 - 2169
    - MELERO, I. ET AL., NAT. MED., (1997), vol. 3, pages 682 - 685
    - HUTLOFF, A. ET AL., NATURE, (1999), vol. 397, pages 262 - 266
    - GREENBERG, R. ET AL., SCIENCE, (1999), vol. 285, pages 546 - 551
    - BUTLER, N.S. ET AL., NATURE IMMUNOLOGY, (2012), vol. 13, pages 188 - 195
    - HOLLIGER, PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - POLJAK, STRUCTURE, (1994), vol. 2, pages 1121 - 1123
    - OVERWIJK, W. ET AL., PROC. NATL. ACAD. SCI. USA, (1999), vol. 96, pages 2982 - 2987
    - SCHENK ET AL., NATURE, (1999), vol. 400, pages 173 - 177
    - RESTIFO ET AL., Cancer Vaccines, pages 3023 - 3043
    - ROSENBERG, IMMUNITY, (1999), vol. 10, pages 281 - 287
    - KIM ET AL., SCIENCE, (1994), vol. 266, pages 2011 - 2013
    - SUOT ET AL., SCIENCE, (1995), vol. 269, pages 1585 - 1588
    - TAMURA ET AL., SCIENCE, (1997), vol. 278, pages 117 - 120
    - NESTLE ET AL., NAT. MED., (1998), vol. 4, pages 328 - 332
    - KUGLER ET AL., NAT. MED., (2000), vol. 6, pages 332 - 336
    - MOKYR ET AL., CANCER RES., (1998), vol. 58, pages 5301 - 5304
    - Phys cians' Desk Reference Supplement, (2004), pages 608 - 610
    - The Pharmacological Basis of Therapeutics, (1975), page 1
    - "Special Methods in Peptide Synthesis, Part A", BARANY, G. ET AL., The Peptides: Analysis, Synthesis, Biology, ACADEMIC PRESS, (1980), vol. 2, pages 3 - 284
    - "The Fluorenylmethoxycarbonyl Amino Protecting Group", ATHERTON, E. ET AL., The Peptides: Analysis, Synthesis, Biology, ACADEMIC PRESS, (1987), vol. 9, pages 1 - 38
    - KING, D.S. ET AL., INT. J. PEPTIDE PROTEIN RES., (1990), vol. 36, pages 255 - 266
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.